# EDGAR Filing Document

**Accession Number:** 0001611746
**File Stem:** 0001213900-26-003668
**Filing Date:** 2026-1
**Character Count:** 63362
**Document Hash:** c8c3932c4041a3c7172ba03e0eb4cd24
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-003668.hdr.sgml**: 20260113

**ACCESSION NUMBER**: 0001213900-26-003668

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 4

**CONFORMED PERIOD OF REPORT**: 20260113

**FILED AS OF DATE**: 20260113

**DATE AS OF CHANGE**: 20260113

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SciSparc Ltd.
- **CENTRAL INDEX KEY:** 0001611746
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38041
- **FILM NUMBER:** 26528396

**BUSINESS ADDRESS:**
- **STREET 1:** 20 RAUL WALLENBERG STREET, TOWER A
- **CITY:** TEL AVIV
- **STATE:** L3
- **ZIP:** 6971916
- **BUSINESS PHONE:** 972-3-6103100

**MAIL ADDRESS:**
- **STREET 1:** 20 RAUL WALLENBERG STREET, TOWER A
- **CITY:** TEL AVIV
- **STATE:** L3
- **ZIP:** 6971916

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SciSparc Ltd./ADR
- **DATE OF NAME CHANGE:** 20210129

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Therapix Biosciences Ltd.
- **DATE OF NAME CHANGE:** 20140624

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of January 2026 (Report No. 2)

Commission File Number: 001-38041

**<u>SCISPARC LTD.</u>**

(Translation of registrant's name into English)

**20 Raul Wallenberg Street, Tower A, <u>Tel Aviv 6971916 Israel</u>**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

**<u>CONTENTS</u>**

On January 8, 2026, SciSparc Ltd. (the "Company") and Xylo Technologies Ltd. ("Xylo") entered into an asset purchase agreement (the "Agreement") pursuant to which the Company agreed to acquire the complete portfolio of patents, trademarks, know-how, brand names and related intellectual property rights, including unregistered intellectual property rights, owned by Xylo. In consideration for these acquired assets, the Company agreed to issue to Xylo an amount of ordinary shares of the Company, which shall represent as of the closing date, 19.99% of the issued and outstanding share capital of the Company (the "Issued Shares"). The Company may elect at its sole discretion to issue, in lieu (in whole or in part) of the Issued Shares, pre-funded warrants to purchase ordinary shares. The Agreement contains customary representations, warranties and covenants of the Company and Xylo, including the Company's obligation to ensure that the Issued Shares shall represent 19.99% of the issued and outstanding share capital of the Company at the closing and to file a registration statement with the U.S. Securities and Exchange Commission (the "SEC") to register the resale of the Issued Shares within 30 days from the Closing Date (as defined below). The closing of the transaction, which is expected on March 8, 2026 (the "Closing Date"), will be subject to customary closing conditions.

The foregoing description of the Agreement set forth above is qualified in its entirety by reference to the full text of the Agreement attached hereto as Exhibit 10.1 to this Report of Foreign Private Issuer on Form 6-K (this "Report").

On January 13, 2026, the Company issued a press release titled "SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity." A copy of this press release is furnished herewith as Exhibit 99.1 to this Report and is incorporated by reference herein.

This Report does not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

This Report is incorporated by reference into the Company's registration statements on Form F-3 (File Nos. [333-286099](http://www.sec.gov/Archives/edgar/data/1611746/000101376225002218/ea0235372-f3_scisparc.htm), [333-275305](http://www.sec.gov/Archives/edgar/data/1611746/000121390023083494/ea187529-f3_scisparc.htm), [333-269839](http://www.sec.gov/Archives/edgar/data/1611746/000121390023012516/ea172999-f3_scisparc.htm), [333-266047](http://www.sec.gov/Archives/edgar/data/1611746/000121390022037966/ea162219-f3_scisparcltd.htm), [333-233417](http://www.sec.gov/Archives/edgar/data/1611746/000121390019016523/ff32019_therapixbio.htm), [333-248670](http://www.sec.gov/Archives/edgar/data/1611746/000121390022022376/ea158932-posam_scisparcltd.htm) and [333-255408](http://www.sec.gov/Archives/edgar/data/1611746/000121390023018886/ea174796-posam_scisparc.htm)) and on Form S-8 (File Nos. [333-278437](http://www.sec.gov/Archives/edgar/data/1611746/000121390024028880/ea0203015-s8_scisparc.htm), [333-225773](http://www.sec.gov/Archives/edgar/data/1611746/000121390018008005/fs82018_therapixbiosciences.htm) and [333-286791](http://www.sec.gov/Archives/edgar/data/1611746/000121390025035801/ea0239224-s8_scisparc.htm)) filed with the SEC to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

***Cautionary Note Regarding Forward-Looking Statements***

This Report contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, the Company uses forward-looking statements when it discusses: the expected acquisition of a portfolio of patents, trademarks and intellectual property rights from Xylo; the Closing Date and the consideration for the acquired assets to be paid to Xylo at closing. Because such statements deal with future events and are based on the Company's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of the Company could differ materially from those described in or implied by the statements in this Report. The forward-looking statements contained or implied in this Report are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in the Company's Annual Report on Form 20-F, as amended, filed with the SEC on April 24, 2025, and in subsequent filings with the SEC. Except as otherwise required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

**<u>EXHIBIT INDEX</u>**

---

| | |
|:---|:---|
| **Exhibit No.** |  |
| 10.1 | [Asset Purchase Agreement, dated January 8, 2026, by and between Xylo Technologies Ltd. and SciSparc Ltd.](ea027253602ex10-1_scisparc.htm) |
| 99.1 | [Press release issued by SciSparc Ltd. titled "SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity."](ea027253602ex99-1_scisparc.htm) |

---

**<u>SIGNATURES</u>**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **SciSparc Ltd.** | **SciSparc Ltd.** |
| Date: January 13, 2026 | By: | /s/ Oz Adler |
|  | Name: | Oz Adler |
|  | Title: | Chief Executive Officer and Chief Financial Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

**ASSET PURCHASE AGREEMENT**

**This Asset Purchase Agreement (the "Agreement"), is made effective as of January 8, 2026 (the "APA Effective Date"), by and between:**

**XYLO Technologies Ltd., a private company organized under the laws of the State of Israel, company registration number 512866971, registered address at 10 Hanechoshet St., Tel Aviv – Yafo 6971072, Israel (the "Seller"); and**

**SciSparc Ltd., a public company organized under the laws of the State of Israel, company registration number 513581652, registered address at 20 Raoul Wallenberg St., Tel Aviv – Yaffo 6971904, Israel (the "Buyer").**

W I T N E S S E T H :

---

| | |
|:---|:---|
| WHEREAS | the Buyer desires to purchase and acquire from Seller, and the Seller desires to sell, assign and transfer to Buyer the Acquired Assets as existing on the Effective Date for the Transaction Consideration (as such terms are defined below), subject, in each case, to the exceptions, terms and conditions set forth herein. |

---

**NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy of which are acknowledged by each of the Seller and the Buyer, the parties hereto, intending to be legally bound hereby, agree as follows:**

**1.**  **<u>PURCHASE AND SALE</u>** 

1.1. <u>Nature of the Transaction and Acquisition and Transfer of Acquired Assets</u>. Upon the terms and subject to the conditions hereinafter
 set forth, at the Closing (as such term is defined below) the Seller shall sell, assign,
 transfer, convey and deliver to the Buyer, and the Buyer shall purchase, acquire and accept
 from the Seller all right, title and interest in and to the Acquired Assets defined
 in this Section 1.1 below, as existing on the Effective Date. The Acquired Assets will be
 sold, assigned, transferred and conveyed to Buyer on the Closing Date (as defined below)
 on an "*As Is* ", "*Where Is*" and "*As Available* "
 basis, with no representations or warranties other than those specifically set forth below.
 At the Closing and subject to the issuance of the Issued Shares (as defined below), the Acquired
 Assets will be transferred and assigned to Buyer free and clear of all liens, encumbrances,
 and other third party rights (other than rights included in the Assumed Liabilities) ()"**Liens** ").

The term "**Acquired Assets**" means:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the Patent Rights listed on  **<u>Schedule 1.1</u>** (the "**Transferred Patent Rights** "), including all claims
 and causes of action with respect to any of the foregoing, whether past, present or future,
 including all rights to and claims for damages, restitution, and injunctive and other legal
 and equitable relief for infringement; "**Patent Rights**" means all patents
 and patent applications (including provisional applications), as well as all renewals, reissues,
 divisions, substitutions, continuations, continuations-in-part, extensions and reexaminations
 and all foreign counterparts thereof, registered or applied for anywhere in the world, together
 with all associated patent files.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Trademarks and brand names as specifically
 listed in each of  **<u>Schedule 1.1 (B)</u>** ()"**Trademarks**") attached
 hereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) certain rights and obligations under
 agreements to which Seller is a party, as listed in  **<u>Schedule 1.1(C)</u>** attached
 hereto (the "**Assigned Contracts** ").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) unregistered intellectual property rights
 owned by Seller that are embodied within the Transferred Patent Rights and Trademarks (such
 as copyrights, trade secrets, use invention rights, past and future rights to sue for infringement),
 in each case, if and to the extent existing and related solely to the Transferred Patent
 Rights and Trademarks (together with the Transferred Patent Rights and Trademarks, collectively,
 the "**Transferred IP Rights** ").

1.2. <u>Excluded Assets</u>. Buyer and Seller
 expressly understand and agree that the Acquired Assets will not include Seller's rights,
 title and assets in and to all other assets of the Seller not specifically listed or described
 in Section 1.1 above (collectively, the "**Excluded Assets** ").

1.3. <u>Assumed Liabilities</u> On the terms and subject to the conditions set forth herein,
 Buyer shall assume and discharge or perform when due only those Liabilities arising out of
 or relating to the Acquired Assets from and after the signing of the binding term sheet,
 dated November 26, 2025 ()"**Effective Date** "),
 including the use, ownership, possession, operation, sale or lease of the Acquired Assets
 (collectively, the "**Assumed Liabilities** "). "**Liabilities**" means any and all
 debts, liabilities, assessments, expenses, claims, losses, damages, deficiencies and obligations,
 whether accrued or fixed, known or unknown, absolute or contingent, matured or unmatured
 or determined or determinable including to the extent applicable liabilities towards the
 Israeli Innovation Authority related to the Acquired Assets.

1.4. <u>Un-Assumed Liabilities</u>.
 As of the Effective Date, and except as specifically set forth in this Agreement, the Buyer
 shall not assume, pay, incur or in any way be liable or responsible for any of the Seller's
 debts, liabilities or obligations, which are not included in the Assumed Liabilities. It
 is agreed that to the extent applicable Seller shall assume the liability to the IIA with
 respect to the payment of the Transaction Consideration.

**2.**  **<u>TRANSACTION CONSIDERATION</u>** 

2.1 In consideration for the sale, transfer, conveyance,
 and assignment of all of the Acquired Assets and Assumed Liabilities, the Buyer shall, subject
 to and upon the Closing, issue to the Seller an amount of ordinary shares, which shall represent
 as of the Closing Date, 19.99% of the issued and outstanding share capital of the Buyer (respectively,
 the "**Transaction Consideration**" and the "**Issued Shares** ").

2.2 The Buyer may elect at its sole discretion
 to issue, in lieu (in whole or in part) of the Issued Shares, prefunded warrants to purchase
 Ordinary Shares, in the form attached hereto as  **<u>Schedule B</u>** (the "**Warrant Shares**" and "**Warrant Certificate"**).

2.3 Registration
 Rights. Buyer shall prepare, and, as soon as practicable but in no event later than 30 days
 from the Closing Date, file with the Commission a registration statement on Form F-3 covering
 the resale of all of the Issued Shares (and/or if applicable Warrant Shares) (the "**Filing Date** "). In the event that Form F-3 is unavailable for such a registration, the
 Company shall use such other form as is available for such a registration on another appropriate
 form reasonably acceptable to the Seller. The Company shall use its reasonable best efforts
 to have the registration statement declared effective by the United States Securities and
 Exchange Commission (the "**Commission**") as soon as practicable, but in
 no event later than the Effectiveness Deadline. "**Effectiveness Deadline** "
 means the date which is the earlier of (x) (i) in the event that the registration statement
 is not subject to a full review by the Commission, sixty (60) calendar days after the Filing
 Date or (ii) in the event that the registration statement is subject to a full review by
 the Commission or in the event that the Company is notified by the Commission to refile the
 registration statement on Form F-1, ninety (90) calendar days after the Filing Date and (y)
 the fifth (5th) Business Day after the date the Company is notified (orally or in writing,
 whichever is earlier) by the Commission that such registration statement will not be reviewed
 or will not be subject to further review; provided, however, that if the Effectiveness Deadline
 falls on a Saturday, Sunday or other day that the Commission is closed for business, the
 Effectiveness Deadline shall be extended to the next Business Day on which the Commission
 is open for business.

2.4 <u>Taxes</u>. Each party shall bear and pay
 all of its own taxes according to applicable laws in connection with the performance of the
 transactions contemplated under this Agreement, including the issuance of the Issued Shares
 and/or the Warrant Shares.

**3.**  **<u>CLOSING</u>**  **<u>& CLOSING DELIVERABLES</u>** 

3.1 <u>Closing & Closing Date</u>. Subject
 to the satisfaction of the conditions set forth in this Section 3 (or the waiver thereof
 by the party entitled to waive that condition), the closing shall take place by exchange
 of signed documentation on March 8, 2026 (the "**Closing**" and the "**Closing Date** ", respectively).

3.2 <u>Proceedings at Closing</u>. All proceedings
 taken, and all documents executed and delivered at the Closing shall be deemed to have been
 taken, executed and delivered simultaneously.

3.3 <u>Conditions to Obligations of each Party to effect the Agreement</u>. The respective obligations of each party to effect the transactions
 contemplated by this Agreement shall be subject to the satisfaction, at or prior to the Closing
 Date, of the following conditions:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3.1 <u>No Law or Order; Illegality</u>.
 No governmental entity shall have enacted, issued, promulgated, enforced or entered any law,
 order or other legal restraint (whether temporary, preliminary or permanent) which is in
 effect and which has the effect of making the transactions contemplated by this Agreement
 illegal or otherwise prohibiting or preventing consummation of the transactions contemplated
 by this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3.2 <u>Accuracy of Representations</u>.
 Each of the representations and warranties made by the parties in this Agreement shall have
 been true and correct in all material respects as of the APA Effective Date, and shall be
 true and correct in all material respects as of the Closing Date as if made on the Closing
 Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3.3 <u>No Injunctive Proceedings</u>.
 No preliminary or permanent injunction or other order (including a temporary restraining
 order) of any court or other governmental agency which prevents the consummation of the transactions
 which are the subject of this Agreement or prohibits Buyer's ownership of the Acquired
 Assets shall have been issued and remain in effect.

3.4 <u>Documents to be delivered by the Seller at Closing</u>. At the Closing, the Seller shall deliver, or cause to be delivered, to the
 Buyer the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4.1 A bill of sale substantially in the
 form attached hereto as  **<u>Schedule 3.4.1</u>** , dated on the Closing Date according
 to which the Seller shall transfer to Buyer the Transferred IP Rights;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4.2 Copies of all necessary corporate
 resolutions adopted by the Seller authorizing the execution of this Agreement and the sale
 of the Acquired Assets to the Buyer in accordance with the terms hereof in the form attached
 hereto as  **<u>Schedule 3.4.2</u>** ; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4.3 Assignment Documents for the due assignment
 of the Transferred IP Rights, in the forms attached hereto as  **<u>Schedule 3.4.3(i)</u>** *(patents)* and  **<u>Schedule 3.4.3(ii)</u>** *(Trademarks).* 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4.4 Seller obtained the consent of the
 parties of the Assigned Contracts for the assignment, in the form to be attached as  **<u>Schedule 3.4.4</u>** .

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4.5 a certificate executed by a duly authorized
 signatory of Seller, dated as of the Closing, certifying that each of the conditions set
 forth in Section 4 (Representations, Warranties and Covenants of Seller) has been satisfied.

3.5 <u>Documents to be delivered by the Buyer at Closing</u>. At the Closing Date, the Buyer shall deliver, or cause to be delivered, to
 the Seller the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.5.1 the applicable restricted book entry
 statement representing the Issued Shares in the name of the Seller and/or the Pre-Funded
 Warrants.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.5.2 Copies of all necessary corporate
 resolutions on part of the Buyer authorizing the execution of this Agreement, the purchase
 of the Acquired Assets by the Buyer and issuance of the Issued Shares and/or the Warrant
 Shares in accordance with the terms thereof in the form attached hereto as  **<u>Schedule 3.5.2</u>** .

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.5.3 a certificate executed by a duly authorized
 signatory of Buyer, dated as of the Closing, certifying that each of the conditions set forth
 in Section 5 (Representations, Warranties and Covenants of Buyer) has been satisfied.

**4.**  **<u>REPRESENTATIONS AND WARRANTIES OF THE SELLER</u>** 

The Acquired Assets will be purchased by Buyer with no representations or warranties, express or implied, by Seller, other than the following specific representations and warranties which Seller hereby represents and warrants to Buyer that will be true and correct as of date hereof and as of the Closing Date:

4.1 <u>Corporate Organization</u>. The Seller
 is a corporation duly organized and validly existing under the laws of the State of Israel
 and has all requisite corporate power and authority to execute, deliver and perform each
 of the Seller Documents (as defined below) and to consummate the transactions contemplated
 thereby.

4.2 <u>Power & Authority; and no Default Upon Transfer</u>. The Seller has full corporate power and authority to execute and deliver this
 Agreement, and each other agreement, document, instrument or certificate which it shall deliver
 to the Buyer at the signing of the Agreement and at the Closing (this Agreement and all of
 such other agreements, documents, instruments and certificates shall be collectively referred
 to herein as the "**Seller Documents** "), and to perform fully its obligations
 under each of the Seller Documents. The execution, delivery and performance by the Seller
 of each of the Seller Documents have been duly authorized by all necessary corporate action
 on the part of the Seller. No other approvals are required in order to consummate the transactions
 contemplated by any of the Seller Documents (except for any such approval which has heretofore
 been duly obtained and continues to be in full force and effect). This Agreement has been,
 and each of the other Seller Documents has been or will at or prior to the Closing be, duly
 executed and delivered by the Seller and (assuming the due authorization, execution and delivery
 by the other parties thereto) each of the Seller Documents constitutes (or, when executed,
 will constitute) a legal, valid and binding obligation of the Seller, enforceable against
 the Seller in accordance with its terms.

4.3 <u>Title to Acquired Assets</u>. Seller has,
 and at the Closing will transfer and deliver to the Buyer, good and valid title to all of
 the Acquired Assets free and clear of all Liens.

4.4 To the knowledge of Seller, all maintenance
 and annual fees that are due and payable have been fully paid, and all fees paid during prosecution
 and after issuance of any patent due and payable have been paid in the correct amounts, in
 each case with respect to the Transferred Patent Rights.

4.5 <u>Assigned Contracts</u>. Neither Seller
 nor any other party to the Assigned Contracts, is in material breach of or default under
 any of such contracts.

4.6 <u>Litigation</u>. There are no actions, suits,
 proceedings or governmental investigations pending or, to Seller's actual knowledge,
 threatened against Seller, before any court, governmental department, commission, board,
 agency, authority or instrumentality, domestic or foreign, that might affect in any way any
 of the Acquired Assets. To the Seller's knowledge, there are no judgments, decrees,
 injunctions or orders of any court, governmental body, department, commission, agency, instrumentality
 or arbitrator against Seller affecting the assignment of the Acquired Assets.

4.7 <u>Consents</u>. No consent, permit, waiver,
 approval, or authorization of, or declaration or filing with, or notification to, any person
 or governmental body is required on the part of the Seller in connection with the execution
 and delivery by the Seller of any of the Seller Documents. Notwithstanding the above, for
 the compliance by the Seller with any of the provisions hereof, including, without limitation,
 the assignment of any Acquired Assets contemplated by this Agreement, the Seller shall assist
 the Buyer with such assignment and transfer of any of the above as is required post-Closing.

4.8 <u>No Other Representations or Warranties</u>.
 Except for the representations and warranties expressly contained in this ‎Section ‎4,
 the Seller does not make any other express or implied representation or warranty.

**5.**  **<u>REPRESENTATIONS AND WARRANTIES OF THE BUYER</u>** 

The Buyer hereby represents and warrants to the Seller as of date hereof and as of the Closing Date as follows:

5.1 <u>Corporate Organization</u>. The Buyer is
 a corporation duly organized and validly existing under the laws of the State of Israel and
 has all requisite corporate power and authority to execute, deliver and perform each of the
 Buyer Documents (as defined below) and to consummate the transactions contemplated thereby;
 to own, lease and operate its properties and other assets and to carry on its business as
 now being conducted. The Buyer is duly qualified or licensed to do business and is in good
 standing in each jurisdiction in which the nature of its business or the ownership or leasing
 of its properties makes such qualification or licensing necessary.

5.2 <u>Power & Authority; and No Default</u>.
 The Buyer has full corporate power and authority to execute and deliver this Agreement and
 each other agreement, document, instrument or certificate which it shall deliver to the Seller
 at the signing of the Agreement and at the Closing (this Agreement and all of such other
 agreements, documents, instruments and certificates shall be collectively referred to herein
 as the "**Buyer Documents**") and to perform fully its obligations under each
 of the Buyer Documents. The execution, delivery and performance by the Buyer of each of the
 Buyer Documents have been duly authorized by all necessary corporate action on the part of
 the Buyer. No other approvals are required in order to consummate the transactions contemplated
 by any of the Buyer Documents (except for any such approval which has heretofore been duly
 obtained and continues to be in full force and effect). This Agreement has been, and each
 of the other Buyer Documents has been or will at or prior to the Closing be, duly executed
 and delivered by the Buyer and (assuming the due authorization, execution and delivery by
 the other parties thereto) each of the Buyer Documents constitutes (or, when executed, will
 constitute) a legal, valid and binding obligation of the Buyer, enforceable against the Buyer
 in accordance with its terms.

5.3 <u>Issued Shares/Warrants</u>. The Issued
 Shares/Warrants, shall represent at the Closing 19.99% of the issued and outstanding capital
 stock of Buyer.

5.4 <u>Capital Structure</u>. Buyer capital structure
 materially conforms to the capital structure described in the Buyer Reports. Except as disclosed
 in the Buyer Reports (as defined below), there are no outstanding bonds, debentures, notes
 or other indebtedness or other securities of Buyer having the right to vote (or convertible
 into, or exchangeable for, securities having the right to vote) on any matters of which stockholders
 of Buyer are entitled to vote on. Except as disclosed in Buyer Reports and as set forth herein,
 there are no outstanding securities, options, warrants, calls, rights, commitments, agreements,
 arrangements or undertakings of any kind to which Buyer is a party or by which it is bound
 obligating Buyer to issue, deliver or sell, or cause to be issued, delivered or sold, additional
 common stock of Buyer or other equity or voting securities of Buyer or obligating Buyer to
 issue, grant, extend or enter into any such security, option, warrant, call, right, commitment,
 agreement, arrangement or undertaking. There are no outstanding contractual obligations,
 commitments, understandings or arrangements of Buyer to repurchase, redeem or otherwise acquire
 or make any payment in respect of any ordinary shares of Buyer or any other securities of
 Buyer. There are no agreements or arrangements pursuant to which Buyer is or could be required
 to register Buyer' ordinary shares or other securities under the Securities Act or
 other agreements or arrangements with or among any holders of Buyer or with respect to any
 securities of Buyer.

5.5 <u>Reports</u>. The Buyer has filed all forms,
 reports and documents with the SEC that have been required to be filed by it under applicable
 laws prior to the date hereof (all such forms, reports and documents, together with
 all documents filed or furnished on a voluntary basis and all exhibits and schedules thereto,
 the "**Buyer Reports** "). As of its filing date (or, if amended or superseded
 by a filing prior to the date of this Agreement, on the date of such amended or superseded
 filing), (i) each Buyer Report complied as to form in all material respects with the applicable
 requirements of the Securities Act, the Exchange Act, and/or the Sarbanes-Oxley Act, as the
 case may be, each as in effect on the date such Buyer Report was filed, and (ii) each Buyer
 Report did not contain any untrue statement of a material fact or omit to state any material
 fact necessary in order to make the statements made therein, in the light of the circumstances
 under which they were made, not misleading. To the knowledge of Buyer, none of the Buyer
 Reports is the subject of ongoing SEC review or investigation. The financial statements of
 Buyer included in the Buyer Reports comply in all material respects with the applicable accounting
 requirements and the rules and regulations of the SEC with respect thereto as in effect at
 the time of filing. The financial statements included in the Buyer Reports have been prepared
 in accordance with International Financial Reporting Standards ()"**IFRS** "),
 and fairly represent the financial position of Buyer and as of and for the dates thereof
 and the results of operations and cash flows for the periods then ended, subject, in the
 case of unaudited statements, to normal, year-end audit adjustments and the omission of certain
 footnotes. Except as set forth in the Buyer Reports, Buyer has no liabilities or obligations
 of any nature (whether accrued, absolute, contingent or otherwise) required by IFRS to be
 set forth on a balance sheet of Buyer or in the notes thereto.

5.6 <u>Litigation</u>. There is no litigation,
 suit, action, arbitration, inquiry, investigation or proceeding pending or, to the knowledge
 of Buyer, threatened, before any court, agency, or other governmental body against Buyer
 (or any corporation or entity affiliated with Buyer) which seeks to enjoin or prohibit or
 otherwise prevent the transactions contemplated hereby.

5.7 <u>Experience; Receipt of Information</u>.
 Buyer has such knowledge and experience in financial and business matters in general and
 in the business of the Seller, in particular, and is capable of evaluating the merits and
 risks relating to the acquisition of the Acquired Assets. The Buyer has been furnished by
 the Seller with documents and information regarding the Acquired Assets, and has been afforded
 the opportunity to ask questions of and receive answers from duly authorized officers or
 other representatives of the Seller concerning the Acquired Assets.

5.8 <u>Consents</u>. No consent, waiver, approval,
 order, permit or authorization of, or declaration or filing with, or notification to, any
 person or governmental body is required on the part of the Buyer in connection with the execution
 and delivery of any of the Buyer Documents or the compliance by the Buyer with any of the
 provisions thereof, except with the SEC and as required for the registration of the Issued
 Shared and/or Warrant Shares.

5.9 <u>Disclosure of Information</u>. The Buyer
 has had an opportunity to discuss the Seller's business, operations, properties, prospects,
 technology, plans, management, financial affairs and the terms and conditions of the offering
 of the Acquired Assets with the Seller's management and has had an opportunity to review
 the Acquired Assets and the business of the Seller.

5.10 <u>Condition of the Acquired Assets.</u> Buyer
 have made all inspections and investigations of the Acquired Assets deemed necessary or desirable
 by Buyer. Buyer acknowledges and agrees that (a) it is purchasing the Acquired Assets based
 on the results of its inspections and investigations, and not on any representation or warranty
 of Seller not expressly set forth in this Agreement and (b) except as otherwise set forth
 in this Agreement, the Acquired Assets are sold "as is, where is" and it accepts
 the Acquired Assets in the condition they are in and at the place where they are located
 on the Closing. In light of these inspections and investigations and the representations
 and warranties expressly made to Buyer by Seller herein, Buyer is relinquishing any right
 to any claim based on any representations and warranties other than those expressly set forth
 in this Agreement and the certificates and other documents delivered pursuant hereto or thereto.
 Any claims Buyer may have for breach of representation or warranty shall be based solely
 on the representations and warranties of Seller set forth in this Agreement and the certificates
 and other documents delivered pursuant hereto or thereto. BUYER ACKNOWLEDGES AND AGREES THAT,
 EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN SECTION 4, NEITHER SELLER, ITS AFFILIATES,
 NOR ANY OTHER PERSON HAS MADE OR MAKES ANY OTHER REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED,
 EITHER IN FACT OR BY OPERATION OF LAW, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY,
 OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR WARRANTY AS TO QUALITY, OR ANY WARRANTY AS
 TO THE VALIDITY OR ENFORCEABILITY OF ANY TRANSFERRED PATENT RIGHTS OR THE NON-INFRINGEMENT
 OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.

**6.** **POST-CLOSING COVENANTS** 

6.1 <u>Transfer and obtaining of Registrations</u>.
 The parties shall diligently transfer to Buyer, at Buyer's sole cost and expense, all
 registrations concerning the Acquired Assets. In this respect Seller shall provide such information,
 documents, powers of attorney, and shall provide such instructions and take such actions,
 etc., all as reasonably required by Buyer and necessary to effect (i) the transfer of the
 Acquired Assets and the registrations thereof; and (ii) the registration of such transfer
 of the Acquired Assets and the registrations with the applicable authorities and institutions
 worldwide in which the Acquired Assets are currently registered in, including but not limited
 to transfer of the registrations of the Transferred IP Rights with the applicable patent
 and trademark authorities and institutions, and subject to compliance and fulfillment of
 Buyer obligations for such actions, including signing any required documents and instruments
 and providing any information, certification or documents required by Seller and/or the respective
 authorities, institutions and registrars for such purpose. From time to time, after the Closing
 Date and during a period of 18 months from the Closing Date, the Seller shall at the reasonable
 request (and with the reasonable cooperation) and at the expense of the Buyer, execute and
 deliver, or use its best efforts to cause to be executed and delivered, all such other and
 further instruments of sale, assignment, assumption, transfer and conveyance and other documents
 and instruments, as may be reasonably required or desirable to confirm or record the Buyer's
 rights in the Acquired Assets and take all such other and further action, as the Buyer may
 reasonably request, in order to vest or perfect the Buyer's right, title and interest
 in and to the Acquired Assets.

6.2 <u>Transferred IP Rights Maintenance</u>.
 Buyer shall be responsible at its own costs, for the preparation, filing, prosecution, protection
 and maintenance of the Assigned Patent Rights in all territories they are currently registered.

6.3 <u>Insurance</u>. Buyer shall maintain insurance
 with respect to its activities under this Agreement regarding the Acquires Assets in such
 amount as such party customarily maintains with respect to similar activities for its other
 products, but not less than such amount as is reasonable and customary in the medical device
 industry. Each insurance policy shall name as additional insureds Seller and their, directors,
 officers, agents and employees and be placed with a reputable insurer with a minimum AM Best
 rating of A- VII, or S&P A, or better.

6.4 <u>Confidentiality and Nondisclosure</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.4.1 The Seller and the Buyer agree that
 all information relating to the Acquired Assets, including but not limited to the following,
 shall be deemed confidential information: business strategies, technology plans, financial
 conditions, business plans, marketing strategies and plans, data, business records, customer
 lists, and any and all information concerning the Acquired Assets that would be deemed confidential,
 a trade secret, a customer list, or other form of proprietary information of the Seller (collectively
 "**Confidential Information** "). The Seller and the Buyer hereby agree, that
 up until the Closing Date all of the Confidential Information shall be solely owned by the
 Seller, and that immediately following the Closing Date all of the Confidential Information
 shall be solely owned by the Buyer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.4.2 The Seller and the Buyer hereby expressly
 agree to maintain such Confidential Information of the other party and not to disclose any
 Confidential Information owned by the other party to any third party. The Seller or Buyer
 may, however, disclose such Confidential Information if required by law or court order, provided
 that the disclosing party gives the other party prior written notice and makes good faith
 best efforts to obtain confidential treatment for such Confidential Information.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.4.3 Notwithstanding the above, Confidential
 Information shall not include any information relating to the Excluded Assets, which shall
 at all times remain the sole property of the Seller and be deemed as Confidential Information
 of the Seller.

6.5 <u>Joint PR</u>. Subject to Section 6.2 above,
 the parties may jointly issue a PR in a form and language as mutually agreed in writing between
 the parties.

**7.** **SURVIVAL AND INDEMNIFICATION** 

7.1 <u>Survival of Representations and Warranties</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The representations and warranties of Seller and Buyer and the covenants and agreements that by their nature are required to be performed at or prior to the Closing, in each case contained in this Agreement, shall survive the Closing and remain in full force and effect until the date that is twelve (12) months from the Closing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) All of the covenants and agreements contained in this Agreement that by their nature are required to be performed after the Closing shall survive the Closing until fully performed or fulfilled, unless and only to the extent that non-compliance with such covenants or agreements is waived by the Party entitled to such performance.

7.2 <u>Indemnified Losses</u>.
 For the purpose of this Section 7.2, and when used elsewhere in this Agreement, the term
 "**Loss**" shall mean and include, any and all direct liability, loss, damage,
 claim, expense, cost, fine, fee, penalty, obligation or injury including, without limitation,
 those resulting from any and all actions, suits, proceedings, demands, assessments, judgments,
 award or arbitration, together with reasonable costs and actual expenses incurred, including
 the reasonable attorneys' fees and other legal costs and direct expenses relating thereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2.1 <u>Indemnification by Seller</u>. Subject
 to the provisions of this Section 7, Seller agrees, from and after the Closing Date, to defend,
 indemnify and hold harmless the Buyer and any director, officer, employee, or attorney thereof,
 from and against any Loss actually suffered or incurred by any Buyer Indemnified Party to
 the extent actually arising from or relating to any: (i) breach of the Seller's representations
 and warranties as set forth in Section 4 above and/or Sellers's covenants under the
 Agreement; (ii) any Excluded Assets; or (iii) any Third Party) claim related to the Excluded
 Assets.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2.2 <u>Indemnification by Buyer</u>. Subject
 to the provisions of this Section 7, Buyer agrees, from and after the Closing Date, to defend,
 indemnify and hold harmless the Seller and any director, officer, employee, or attorney thereof,
 from and against any Loss actually suffered or incurred by such Seller Indemnified Party
 to the extent arising from or relating to any: (i) breach of the Buyer's representations
 and warranties as set forth in Section 5 above and/or Buyer's covenants under the Agreement;
 (ii) use, ownership, possession, operation, sale, lease, service or other exploitation of
 any of the Acquired Assets from and after the Closing; or (iii) any Assumed Liability.

Any person providing indemnification pursuant to the provisions of this 7 is hereinafter referred to as an "**Indemnifying Party**" and any person entitled to be indemnified pursuant to the provisions of this ‎Section 7 is hereinafter referred to as an "**Indemnified Party**".

7.3 The right for indemnification provided under
 this Agreement is the parties' exclusive remedy for any breach of the representations,
 warranties, covenants, agreements, and obligations in this Agreement. Any claim for indemnification
 under this Agreement, may only be asserted and filed by the parties within the Survival Period,
 and with respect to either of the parties' covenants and agreements contained in this
 Agreement, that by their nature are required to be performed after the Closing and/or the
 Survival Period, shall survive the Closing and the Survival Period until fully performed
 or fulfilled.

7.4 <u>Procedures for Third Party Claims</u>.
 In the case of any claim of a third party that may reasonably give rise to Losses, for which
 an Indemnifying Party may be liable for indemnification under this Section 7 (a "**Third Party Claim** "), an Indemnified Party shall give prompt written notice to the Indemnifying
 Party of any claim or demand which such Indemnified Party has knowledge and as to which it
 may request indemnification hereunder. Each claim notice shall (A)(1) specify in reasonable
 detail all relevant facts, conditions and events, and (2) identify the specific provisions
 of this Agreement which give rise to such indemnification right; and (B) include a good-faith
 estimate of the amount of Losses for which the Indemnified Party is seeking indemnification
 from the Indemnifying Party. The Indemnifying Party shall have the right to defend and to
 direct the defense against any such Third Party Claim, in its name or in the name of the
 Indemnified Party, as the case may be, at the expense of the Indemnifying Party, and with
 counsel selected by the Indemnifying Party unless: (a) such Third Party Claim seeks an order,
 injunction or other equitable relief against the Indemnified Party, or (b) the Indemnified
 Party shall have reasonably concluded that (i) there is a conflict of interest between the
 Indemnified Party and the Indemnifying Party in the conduct of the defense of such Third
 Party Claim, or (ii) the Indemnified Party has one or more defenses not available to the
 Indemnifying Party. Notwithstanding anything in this Agreement to the contrary, the Indemnified
 Party shall, at the expense of the Indemnifying Party, cooperate with the Indemnifying Party,
 and keep the Indemnifying Party fully informed, in the defense of such Third Party Claim.
 The Indemnified Party shall have the right to participate in the defense of any Third Party
 Claim with counsel employed at its own expense; provided, however, that, in the case of any
 Third Party Claim described in clause (a) or (b) of the second preceding sentence or as to
 which the Indemnifying Party shall not in fact have employed counsel to assume the defense
 of such Third Party Claim, the reasonable fees and disbursements of such counsel shall be
 at the expense of the Indemnifying Party. The Indemnifying Party shall have no indemnification
 obligations with respect to any Third Party Claim which shall be settled by the Indemnified
 Party without the prior written consent of the Indemnifying Party, which consent shall not
 be unreasonably withheld, delayed or conditioned.

7.5 <u>Procedures for Inter-Party Claims</u>.
 In the event that an Indemnified Party determines that it has a claim for Losses against
 an Indemnifying Party hereunder (other than as a result of a Third Party Claim), the Indemnified
 Party shall give prompt written notice thereof to the Indemnifying Party, specifying the
 amount of such claim and any relevant facts and circumstances relating thereto. The Indemnified
 Party shall provide the Indemnifying Party with reasonable access to its books and records
 for the purpose of allowing the Indemnifying Party a reasonable opportunity to verify any
 such claim for Losses. The Indemnified Party and the Indemnifying Party shall negotiate in
 good faith regarding the resolution of any disputed claims for Losses. In the event of disagreement
 on the Losses, the Indemnified Party shall be entitled to submit a claim to the authorized
 court in Israel against the Indemnifying Party and the cost of such proceedings (including
 costs of investigation and reasonable attorney fees and disbursements) shall be awarded to
 the prevailing party.

7.6 Notwithstanding anything to the contrary in
 this Agreement, the total aggregate liability of any Indemnifying Party to pay indemnification
 amounts, is expressly limited as set forth in each and all of the provisions below: (i) 
 where the Losses incurred by the Indemnified Party exceeds USD 100,000 (the "**Deductible** "),
 at which time only such Losses in excess of the Deductible will be subject to indemnification
 hereunder; and (ii) Seller's or Buyer's aggregate Liability for indemnification
 pursuant to this Section 7, unless arising in connection with fraud or Third Party Claims,
 will not exceed fifteen percent (15%) of the value of the Transaction Consideration
 at the Closing date.

7.7 Notwithstanding anything to the contrary contained
 herein, neither party shall be liable for any (i) special, punitive, exemplary, incidental,
 consequential or indirect damages, (ii) lost profits or lost business, loss of enterprise
 value, diminution in value of any business, damage to reputation or loss of goodwill; or
 (iii) damages calculated based on a multiple of profits, revenue or any other financial metric,
 in each case, whether based on contract, tort, strict liability, other laws or otherwise,
 and whether or not arising from any other party's sole, joint or concurrent negligence,
 strict liability or other fault.

7.8 <u>Sole Remedy; Waiver</u>. Each Party acknowledges
 and agrees that the remedies provided for in this Agreement shall be its sole and exclusive
 remedy with respect to the subject matter of this Agreement. In furtherance of the foregoing,
 each of the Parties hereby waives, to the fullest extent permitted by applicable Law, any
 and all other rights, claims and causes of action (including rights of contributions, if
 any) known or unknown, foreseen or unforeseen, which exist or may arise in the future, that
 it may have against Seller, or Buyer or any of their Indemnified Parties, as the case may
 be, arising under or based upon any applicable Law, except that nothing herein shall limit
 the liability of either Party for fraud.

**8.** **TERMINATION** 

8.1 This Agreement may be terminated and the transactions
 contemplated hereby abandoned at any time prior to the Closing: (i) by mutual written agreement
 of Seller and Buyer; (ii) by either party – in the event that any of the Conditions
 to obligations of each Party to effect the Agreement, as set forth in Section 3.3 above,
 has not been met by the Closing Date; or (iii) by Buyer or Seller - in the event that any
 of the Conditions precedent to the obligations of each Buyer or Seller, as set forth in Section
 3.4 or 3.5 above, has not been met by the Closing Date.

8.2 In the event of termination of this Agreement
 as provided above, this Agreement shall be of no further force and effect and there shall
 be no further obligations on the part of Buyer or Seller or their respective officers, directors,
 shareholders, affiliates or representatives; provided, however, that notwithstanding anything
 herein to the contrary, Section 6.2 (Confidentiality), this Section 8.2 and Section 9 (Miscellaneous),
 will remain in full force and effect and survive any termination of this Agreement; and nothing
 herein will relieve any party hereto from liability arising out of or resulting from any
 fraud or intentional breach occurring prior to such termination.

 

**9.**  **<u>MISCELLANEOUS</u>** 

9.1 <u>Entire Agreement</u>. This Agreement (including
 the schedules hereto) is intended as, a complete statement of all of the terms and the arrangements
 between the parties hereto with respect to the matters provided for herein or therein, and
 supersedes any and all previous agreements and understandings, written and oral, between
 the parties hereto with respect to those matters, including the Binding Term Sheet for the
 Sale of Patent Portfolio & Trademarks executed between the parties dated November 26,
 2025.

9.2 <u>Further Assurances</u>. Each party agrees
 that it will execute and deliver, or cause to be executed and delivered, on or after the
 date of this Agreement and after the Closing, all such other instruments and will take all
 reasonable actions as may be necessary to transfer and convey the Acquired Assets to Buyer,
 on the terms herein contained, and to consummate the transactions herein contained to effectuate
 the provisions and purposes hereof.

9.3 <u>Governing Law</u>. This Agreement shall
 be exclusively governed by and construed in accordance with the laws of the State of Israel,
 without giving effect to principles of conflicts of law. The courts of Israel (in either
 Tel-Aviv or the city of Haifa) will have exclusive jurisdiction over all claims arising out
 of or relating to this Agreement and any ancillary document related thereto, and each party
 hereby consents and submits to such exclusive jurisdiction.

9.4 <u>No Waiver</u>. No failure or delay by either
 party in exercising any right, power or privilege hereunder shall operate as a waiver thereof,
 nor shall any single or partial exercise thereof preclude any other, or further, exercise
 thereof or the exercise of any other right, power or privilege.

9.5 <u>Expenses</u>. Each of the parties hereto
 shall bear its own expenses (including, without limitation, fees and disbursements of its
 counsel, accountants and other experts), incurred by it in connection with the preparation,
 negotiation, execution, delivery and performance of this Agreement, each of the other documents
 and instruments executed in connection with or contemplated by this Agreement and the consummation
 of the transactions contemplated hereby and thereby; provided, however, that Buyer shall
 be responsible for all fees and expenses associated with the transfer of title to the Acquired
 Assets from Seller to Buyer. If the Seller actually pays any of those amounts on behalf of
 Buyer than Buyer shall indemnify Seller for those expenses.

9.6 <u>Notices</u>. All notices, requests, permissions,
 waivers, and other communications hereunder shall be in writing and shall be deemed to have
 been duly given, (a) five business days following sending by registered or certified mail,
 postage prepaid, (b) one business day after it was sent, if sent by electronic mail or other
 forms of electronic messaging; *provided* that the such electronic transmission is confirmed
 by telephone or by electronic means, (c) when delivered, if delivered personally to the intended
 recipient, and (d) one business day following sending by overnight delivery via a national
 courier service, and in each case, addressed to a party at the following address for such
 party:

---

| | |
|:---|:---|
| If to the Seller, to: | **XYLO Technologies Ltd.**<br> 10 Hanechoshet St., Tel Aviv – Yafo 6971072, Israel<br> Attn: __________________<br> e-mail: __________________ |
| With a copy to (which shall not be deemed as due notice): | **Primes & Co. – Law Firm**<br> 16 Derech Hayam, Haifa 34741, Israel<br> Attn: Adv. Meytal Katz, Partner<br> e-mail: meytal@pgs-law.co.il |
| If to the Buyer, to:<br>| **SciSparc Ltd.**<br> 20 Raoul Wallenberg St., Tel Aviv – Yaffo 6971904, Israel<br> Attn: Oz Adler<br> e-mail: Oz@scisparc.com |
| With a copy to (which shall not be deemed as due notice): | Meitar \| Law Offices<br> Address: 16 Abba Hillel Road, Ramat Gan, 5250608, Israel<br> Attn: Dr. Shachar Hadar, Partner<br> e-mail: Shacharh@metiar.com |

---

or to such other address(es) as shall be furnished in writing by any such party to each of the other parties hereto in accordance with the provisions of this Section 9.6.

9.7 <u>Binding Effect</u>. This Agreement shall
 be binding upon and inure to the benefit of the parties and their respective successors and
 assigns.

9.8 <u>Amendments</u>. This Agreement may be amended,
 supplemented or modified, and any provision hereof may be waived, only pursuant to a written
 instrument making specific reference to this Agreement signed by each of the parties hereto.

9.9 <u>No Presumption; Waiver</u>. Each of the
 parties agrees, represents and acknowledges that it was duly represented in this Agreement,
 its drafting, negotiations and in the underlying transaction, with such legal counsel of
 its choice, and that neither party is relying on the representation and legal counsel or
 advice of the other party.

9.10 <u>Counterparts</u>. This Agreement may be
 executed in any number of counterparts, each of which shall be deemed an original, but all
 of which together shall constitute one and the same instrument.

*[Intentionally left blank – next page is the signature page]*

 

*[Signature Page to the Asset Purchase Agreement, between XYLO & SciSparc, dated January 8, 2026]*

 

**IN WITNESS WHEREOF**, the parties hereto have executed this Agreement as of the APA Effective Date.

---

| | | | |
|:---|:---|:---|:---|
| /s/ Xylo Technologies Ltd. | /s/ Xylo Technologies Ltd. | /s/ SciSparc Ltd. | /s/ SciSparc Ltd. |
| **XYLO TECHNOLOGIES LTD.**<br> (Seller) | **XYLO TECHNOLOGIES LTD.**<br> (Seller) | **SCISPARC LTD.**<br> (Buyer) | **SCISPARC LTD.**<br> (Buyer) |
| By its Authorized Signatory | By its Authorized Signatory | By its Authorized Signatory | By its Authorized Signatory |
| Name: | Eli Yoresh | Name: | Oz Adler |
| Title: | Chief Executive Officer | Title: | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](ex99-1_001.jpg)

**SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity**

 

*SciSparc intends to commence commercialization of these patented technologies immediately following the transaction closing*

TEL AVIV, Israel, Jan. 12, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., announced today the signing of a definitive agreement to acquire a treasury of patents, trademarks and intellectual property rights for innovative endoscopic systems and medical cameras, including the MUSE™ system, from Xylo Technologies Ltd. ("Xylo").

The MUSE™ system is a single-use, innovative endoscopic device designed for transoral fundoplication, a minimally invasive procedure to treat gastroesophageal reflux disease ("GERD").

SciSparc intends to commence commercialization of these patented technologies immediately following the transaction closing, building on the established foundation to drive rapid market penetration and revenue generation.

Building on Xylo's successful commercialization in Greater China through licensing and distribution agreement with a Shanghai-based medical instruments company in 2019, under which Xylo received $3 million up front, SciSparc seeks to replicate this proven model across high-growth territories, such as North America, Europe and Latin America, by pursuing similar exclusive partnerships with leading regional distributors to accelerate global commercialization and unlock substantial revenue streams.

Under the terms of the definitive agreement, SciSparc will acquire the complete portfolio of patents, trademarks, know-how, and related intellectual property rights, mainly associated with the MUSE™ system, from Xylo. In consideration for the acquired assets, SciSparc will issue to Xylo, upon the closing of the transaction (the "Closing"), an amount of ordinary shares of the Company, which shall represent, as of the Closing date, which is set on March 8, 2026, 19.99% of the issued and outstanding share capital of SciSparc (the "Issued Shares"). SciSparc may elect, at its sole discretion, to issue, in lieu (in whole or in part) the Issued Shares, pre-funded warrants to purchase ordinary shares.

The transaction remains subject to customary closing conditions, including any required regulatory approvals.

According to a May 2025 market research report by MarkNtel Advisors, the global GERD device market was valued at approximately $2.5 billion in 2024 and is projected to reach $3.03 billion by 2030, growing at a compound annual growth rate (CAGR) of 3.24% from 2025 to 2030.

 

*This press release does not constitute an offer of securities for sale in the United States. The securities referred to herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), and such securities may not be offered or sold within the United States absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act.*

**About SciSparc Ltd. (Nasdaq: SPRC):**

The Company, through its majority-owned subsidiary NeuroThera Labs Inc., engages in clinical-stage pharmaceutical developments. SciSparc's focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera Labs Inc., are currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation; and SCI- 210 for the treatment of ASD and status epilepticus. The Company, through NeuroThera Labs Inc., also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace.

**Forward-Looking Statements:**

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses: the expected acquisition of a portfolio of patents, trademarks and intellectual property rights for innovative endoscopic systems and medical cameras, including the MUSE <sup>TM</sup> system from Xylo; the consideration for the acquired assets to be paid to Xylo at Closing; the Company's plans to replicate Xylo's licensing and distribution model from Greater China to other territories, such as North America, Europe and Latin America; the Company's plans to pursue exclusive partnerships with leading regional distributors to accelerate commercialization and unlock substantial revenue streams; the Closing Date, the Company's intention to commercialize these patented technologies and the timing thereof and the expected value and growth of the global GERD device market. The acquisition of the intellectual property assets described in this press release is subject to customary closing conditions, including any required regulatory approvals. Because such statements deal with future events and are based on SciSparc's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in SciSparc's Annual Report on Form 20-F, as amended, filed with the SEC on April 24, 2025, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Investor Contact:

IR@scisparc.com<br> Tel: +972-3-6167055